2-(1-Ethyl-3-piperidinyl)acetic acid | 1220038-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(1-Ethyl-3-piperidinyl)acetic acid
• 英文别名: 2-(1-ethylpiperidin-3-yl)acetic acid
• CAS: 1220038-66-3
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: RUGIGIGUQLTGGH-UHFFFAOYSA-N

物化性质

• 沸点：
  285.9±13.0 °C(Predicted)
• 密度：
  1.023±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-amino-4,6-dichloro-3-(3,4-dichlorophenyl)-1H-indol-2-one 、 2-(1-Ethyl-3-piperidinyl)acetic acid 在 五氯化磷 、 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 5.34h， 以28%的产率得到N-[4,6-dichloro-3-(3,4-dichlorophenyl)-2-oxo-1H-indol-3-yl]-2-(1-ethylpiperidin-3-yl)acetamide
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists

  摘要：

  The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.018
• 作为产物：
  描述：

  1-乙基哌啶-3-酮 在 盐酸 、 potassium carbonate 、 magnesium 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 40.58h， 生成 2-(1-Ethyl-3-piperidinyl)acetic acid
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists

  摘要：

  The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.018

文献信息

• TLR7/8 antagonists and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10836750B1

  公开（公告）日：2020-11-17

  Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.

  本文描述了可用作 TLR7/8 拮抗剂的式 I 化合物及其药学上可接受的组合物。
• PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：EP0983269A1

  公开（公告）日：2000-03-08
• EP0983269A4
  申请人：——

  公开号：EP0983269A4

  公开（公告）日：2001-06-27
• TLR7/8 ANTAGONISTS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20200369648A1

  公开（公告）日：2020-11-26

  Compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists, are described herein.
• [EN] PROCESS FOR PREPARING HETEROCYCLIC COMPOUNDS<br/>[FR] PROCEDE UTILES POUR LA PREPARATION DE COMPOSES HETEROCYCLIQUES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1998054179A1

  公开（公告）日：1998-12-03

  (EN) The present invention provides a process for preparing thiadiazole azabicyclic compounds.(FR) La présente invention concerne un procédé utile pour la préparation de composés azabicycliques de thiadiazole.